OverviewSuggest Edit

SIGA Technologies is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The Company's lead product is TPOXX an orally administered antiviral drug that targets orthopoxvirus infections. While TPOXX is not yet approved as safe or effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the U.S. Strategic National Stockpile under the Project BioShield Act of 2004.

TypePublic
HQNew York, US
Websitesiga.com
Employee Ratings2.2

Latest Updates

Employees (est.) (Feb 2020)41
Revenue (FY, 2019)$26.7 M(-94%)
Share Price (Oct 2020)$6.9 (+2%)
Cybersecurity ratingAMore

Key People/Management at SIGA Technologies

Phillip L Gomez

Phillip L Gomez

Chief Executive Officer
Dennis E. Hruby

Dennis E. Hruby

Chief Scientific Officer
Robin E. Abrams

Robin E. Abrams

General Counsel and Chief Administrative Officer
Daniel J. Luckshire

Daniel J. Luckshire

Executive Vice President and Chief Financial Officer
C. Bolken

C. Bolken

Senior Vice President, Operations
Herb Vloedman

Herb Vloedman

Chief Information Officer
Show more

SIGA Technologies Office Locations

SIGA Technologies has offices in New York and Corvallis
New York, US (HQ)
31 E 62nd St
Corvallis, US
4575 SW Research Way #110
New York, US
660 Madison Ave #1700
Show all (3)

SIGA Technologies Financials and Metrics

SIGA Technologies Revenue

SIGA Technologies's revenue was reported to be $26.74 m in FY, 2019
USD

Revenue (Q2, 2020)

40.3m

Gross profit (Q2, 2020)

35.6m

Gross profit margin (Q2, 2020), %

88.1%

Net income (Q2, 2020)

20.9m

EBIT (Q2, 2020)

28.8m

Market capitalization (16-Oct-2020)

535.9m

Closing stock price (16-Oct-2020)

6.9

Cash (30-Jun-2020)

53.1m
SIGA Technologies's current market capitalization is $535.9 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

477.1m26.7m

Cost of goods sold

95.3m1.8m

Gross profit

381.8m25.0m

Gross profit Margin, %

80%93%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

471.1m10.5m3.9m8.1m2.6m40.3m

Cost of goods sold

95.2m915.4k737.3k109.1k4.8m

Gross profit

375.9m9.5m3.9m7.4m2.5m35.6m

Gross profit Margin, %

80%91%100%91%96%88%
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

SIGA Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

SIGA Technologies Online and Social Media Presence

Embed Graph

SIGA Technologies News and Updates

SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX®

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office for Chemical, Biolo…

SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019

NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) As…

SIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019

NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis E. Hruby, the Company’s Chief Scientific Officer, will be a speaker at the 13th Chemical, Bio…

SIGA Technologies CEO to Speak at NCT Europe on June 27, 2019

NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) Eu…

SIGA Technologies to Host Business Update Webcast on June 18, 2019

NEW YORK, June 11, 2019 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesda…

SIGA Technologies to Ring the Nasdaq Opening Bell on Friday, September 14, 2018

NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that that management will be ringing the Nasdaq Stock Market Opening Bell on Friday, September 14, 2018. The …
Show more

SIGA Technologies Blogs

SIGA Technologies Announces First International Delivery of Oral TPOXX®

SIGA Technologies Announces First International Delivery of Oral TPOXX® Content Import Mon, 06/01/2020 - 09:02 SIGA Technologies Announces First International Delivery of Oral TPOXX® June 1, 2020 at 9:01 AM EDT This release is a backfill from a News Wire …

SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020

SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020 Content Import Wed, 05/06/2020 - 16:05 SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020 May 6, 2020 at 4:05 PM EDT This release is a backfill from a …

SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX®

SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX® Content Import Wed, 04/29/2020 - 16:31 SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX® April 29, 2020 a…

SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results

NEW YORK , April 29, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M.

SIGA Technologies, Inc. Reports Financial Results for  Fiscal Year 2019

SIGA Technologies, Inc. Reports Financial Results for  Fiscal Year 2019 Content Import Thu, 03/05/2020 - 16:06 SIGA Technologies, Inc. Reports Financial Results for  Fiscal Year 2019 March 5, 2020 at 4:05 PM EST This release is a backfill from a News Wire …

SIGA Announces Collaboration with Turnstone Biologics

SIGA Announces Collaboration with Turnstone Biologics Content Import Mon, 03/02/2020 - 16:30 SIGA Announces Collaboration with Turnstone Biologics March 2, 2020 at 4:30 PM EST This release is a backfill from a News Wire General SIGA t…
Show more

SIGA Technologies Frequently Asked Questions

  • Who are SIGA Technologies key executives?

    SIGA Technologies's key executives are Phillip L Gomez, Dennis E. Hruby and Robin E. Abrams.

  • How many employees does SIGA Technologies have?

    SIGA Technologies has 41 employees.

  • What is SIGA Technologies revenue?

    Latest SIGA Technologies annual revenue is $26.7 m.

  • What is SIGA Technologies revenue per employee?

    Latest SIGA Technologies revenue per employee is $652.2 k.

  • Who are SIGA Technologies competitors?

    Competitors of SIGA Technologies include Obsidian Therapeutics, Mymetics and Elite Pharmaceuticals.

  • Where is SIGA Technologies headquarters?

    SIGA Technologies headquarters is located at 31 E 62nd St, New York.

  • Where are SIGA Technologies offices?

    SIGA Technologies has offices in New York and Corvallis.

  • How many offices does SIGA Technologies have?

    SIGA Technologies has 3 offices.